Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Alzheimer's Disease Health Center

Font Size

Alzheimer’s Drug Nothing to Sneeze At

Used for Decades as an Allergy Drug, Dimebon now Shows Promise in Treating Alzheimer’s Patients
WebMD Health News
Reviewed by Louise Chang, MD

April 17, 2008 -- A nearly forgotten allergy drug first used in Russia more than two decades ago is showing promise for the treatment of Alzheimer's disease.

In a study of the antihistamine Dimebon, Alzheimer's patients with mild to moderate disease continued to show improvements in memory, thinking, and daily and overall functioning over six months of treatment.

Some patients showed improvements when treated for up to a year.

Results from the Russian study were presented this week at the 60th annual meeting of the American Academy of Neurology (AAN) in Chicago. Study results were also reported last summer at an international conference on Alzheimer's disease.

Dimebon Alzheimer's Trial

Dimebon was approved as an antihistamine in Russia in the early 1980s.

It attracted attention as a potential Alzheimer's treatment following positive animal studies in 2000.

The human trial conducted in Russia included 183 patients with mild-to-moderate disease treated for six months with either Dimebon or placebo. Some patients continued to take the antihistamine for as long as a year.

Researchers reported significant improvement in memory, thinking, and other cognitive measures over placebo in as little as 12 weeks, and the differences were maintained over six months to a year.

Tests to measure mental function and interviews with caregivers confirmed improvements or disease stabilization in 81% of the Dimebon-treated patients after six months.

In a presentation delivered Thursday at the AAN meeting, Steven H. Ferris, PhD, reported that the drug's impact in Alzheimer's patients appears to be broad, rather than selective.

Ferris directs the Alzheimer's Disease Center at NYU School of Medicine.

"Our sub-analysis of the trial results suggests a broad, general benefit affecting language, memory, and other domains of cognition," Ferris tells WebMD.

International Trial Planned

The biopharmaceutical company Medivation Inc., which hopes to market Dimebon for the treatment of Alzheimer's in the U.S., is funding a second study of the drug to be conducted in the U.S., Europe, and South America.

If the earlier findings are confirmed, Medivation Inc. CEO David Hung, MD, tells WebMD that the company plans to petition the FDA for the drug's approval as an Alzheimer's treatment in 2010.

Today on WebMD

Remember your finger
When it’s more than just forgetfulness.
senior man with serious expression
Which kinds are treatable?
senior man
Common symptoms to look for.
mri scan of human brain
Can drinking red wine reverse the disease?
eating blueberries
Colored mri of brain
Close up of elderly couple holding hands
mature woman
Woman comforting ailing mother
Senior woman with serious expression